Key Takeaways:
- Greenwich LifeSciences posted a Q4 loss of $0.58 per share
- The result missed the $0.33 consensus estimate by $0.25
- The pre-revenue biotech advances its breast cancer vaccine candidate
Back
Greenwich LifeSciences posts $0.58 Q4 loss, wider than $0.33 estimate
Greenwich LifeSciences Inc. reported a fourth-quarter loss of $0.58 per share, wider than the $0.33 loss analysts had expected. The clinical-stage biotech recorded zero revenue for the period ended Dec. 31, 2025, matching estimates.
"The quarter reflects our continued investment in the Phase 3 clinical trial of GP2, our lead immunotherapy candidate for breast cancer," Chief Executive Officer Snehal Patel said. The company ended the quarter with cash sufficient to fund operations into 2027, according to its filing.
The $0.25 per-share miss was driven by higher research and development expenses as the company expanded enrollment in its GP2 trial. Greenwich LifeSciences reported no revenue, consistent with its pre-commercial status as a clinical-stage biotechnology company focused on developing immunotherapies for solid tumors.
GP2 is a HER2-targeting immunotherapy designed to prevent breast cancer recurrence in patients who have completed standard treatment. The Phase 3 trial is enrolling patients across multiple sites in the United States. If successful, GP2 could address a significant unmet need in the adjuvant breast cancer treatment market, where recurrence remains a major risk for HER2-positive patients.
The wider loss highlights the capital-intensive nature of late-stage drug development. Investors will watch for interim data from the GP2 Phase 3 trial, which is evaluating the vaccine's efficacy in preventing breast cancer recurrence. The company has not yet set a date for the next data readout.
This article is for informational purposes only and does not constitute investment advice.
